IP Library Patent Application 16882660
Patent Application
App. No. 16/882,660

PEPTIDE COMPOSITIONS AND RELATED METHODS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
16/882,660
Abstract

Peptide compositions and methods for inhibiting neovascularization or development of pathological or aberrant blood vessels in human or other animal subjects.

Claims (23)

1 .- 23 . (canceled)

24 . A method for inhibiting neovascularization or the development of pathological or aberrant blood vessels in a human or animal subject who is in need thereof, said method comprising the step of administering to the subject a therapeutically effective amount of a composition comprising a peptide which consists of or includes an amino acid sequence having the formula

Y—X—Z

wherein:

Y=R, H, K, Cys(acid), G or D;

X=G, A, Cys(acid), R, G, D or E; and

Z=Cys(acid), G, C, R, D, N or E.

25 . A method according to claim 24 wherein the composition further comprises taurine.

26 . A method according to claim 24 wherein the method is carried out to inhibit neovascularization or the development of pathological or aberrant blood vessels in the eye.

27 . A method according to claim 26 wherein the method is carried out to treat a disease or disorder selected from: diabetic retinopathy, neovascular age-related macular degeneration, retinopathy of prematurity (ROP), sickle cell retinopathy, retinal vein occlusion, ischemia-induced retinopathy and inflammatory diseases of the eye.

28 . A method according to claim 24 wherein the method is carried out to inhibit neovascularization or the development of pathological or aberrant blood vessels outside of the eye.

29 . A method according to claim 28 wherein the method is carried out to inhibit the growth or metastasis of a vascularized tumor.

30 . A method according to claim 24 wherein the peptide comprises R-G-Cys(acid)-G-G-G-D-G.

31 . A method according to claim 24 wherein the peptide comprises Cyclo-{R-G-Cys(acid)-F-N-Me-V}.

32 . A method according to claim 24 wherein the amino acid sequence is R-A-Cys (acid).

33 . A method according to claim 24 wherein the amino acid sequence is Cys(acid)-G-R.

34 . A method according to claim 24 wherein the peptide comprises Cyclo-{R-G-D-D-F-NMe-V}.

35 . A method according to claim 24 wherein the amino acid sequence is H-G-Cys(acid).

36 . A method according to claim 24 wherein the amino acid sequence is R-G-N.

37 . A method according to claim 24 wherein the amino acid sequence is D-G-R.

38 . A method according to claim 24 wherein the amino acid sequence is R-D-G.

39 . A method according to claim 24 wherein the amino acid sequence is R-A-E.

40 . A method according to claim 24 wherein the amino acid sequence is K-G-D.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 10, 2024
From: ALLEGRO PHARMACEUTICALS, L.L.C.
To: JENIUS PHARMA, LLC
Reel/Frame 067376/0103 →